View in EDS

POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China.

Saved in:
Bibliographic Details
Title: POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China.
Authors: Hu, J1 (AUTHOR), Sutherland, CS2 (AUTHOR), Aponte Ribero, V2 (AUTHOR), Zhu, L1 (AUTHOR), Hou, X3 (AUTHOR), Xia, Y4 (AUTHOR), Tang, M4 (AUTHOR), Jin, C1 (AUTHOR), Kang, Q1 (AUTHOR)
Source: Value in Health. 2022 Supplement, Vol. 25 Issue 1, pS105-S105. 1p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first